CN115279761B - 咪唑并吡啶酮化合物或其盐的晶体 - Google Patents

咪唑并吡啶酮化合物或其盐的晶体 Download PDF

Info

Publication number
CN115279761B
CN115279761B CN202180020393.0A CN202180020393A CN115279761B CN 115279761 B CN115279761 B CN 115279761B CN 202180020393 A CN202180020393 A CN 202180020393A CN 115279761 B CN115279761 B CN 115279761B
Authority
CN
China
Prior art keywords
peaks
compound
powder
salt
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180020393.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN115279761A (zh
Inventor
竹内秀树
木岛喜朗
森山彰博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of CN115279761A publication Critical patent/CN115279761A/zh
Application granted granted Critical
Publication of CN115279761B publication Critical patent/CN115279761B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180020393.0A 2020-03-11 2021-03-10 咪唑并吡啶酮化合物或其盐的晶体 Active CN115279761B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-041453 2020-03-11
JP2020041453 2020-03-11
PCT/JP2021/009405 WO2021182490A1 (ja) 2020-03-11 2021-03-10 イミダゾピリジノン化合物又はその塩の結晶

Publications (2)

Publication Number Publication Date
CN115279761A CN115279761A (zh) 2022-11-01
CN115279761B true CN115279761B (zh) 2025-03-14

Family

ID=77672382

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180020393.0A Active CN115279761B (zh) 2020-03-11 2021-03-10 咪唑并吡啶酮化合物或其盐的晶体

Country Status (8)

Country Link
US (1) US20230167108A1 (https=)
EP (1) EP4091670A4 (https=)
JP (1) JP7566008B2 (https=)
KR (1) KR20220152276A (https=)
CN (1) CN115279761B (https=)
AU (1) AU2021233433A1 (https=)
CA (1) CA3169000A1 (https=)
WO (1) WO2021182490A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7654426B2 (ja) * 2020-03-12 2025-04-01 キッセイ薬品工業株式会社 イミダゾピリジノン化合物の製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112689637A (zh) * 2018-09-13 2021-04-20 橘生药品工业株式会社 咪唑并吡啶酮化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
US20070142369A1 (en) * 2005-12-21 2007-06-21 Margaret Van Heek Combination of an H3 antagonist/inverse agonist and an appetite suppressant
EP2160187B1 (en) 2007-05-16 2013-05-22 Merck Sharp & Dohme Corp. Spiroindalones
CA2696725A1 (en) * 2007-08-10 2009-03-26 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
CA2698071A1 (en) 2007-08-27 2009-03-05 Wyeth Llc Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
EP2285375B1 (en) 2008-05-08 2013-04-10 Merck Sharp & Dohme Corp. spiroazaindole compounds as HIF propylhydroxylase inhibitors
SI2455381T1 (sl) * 2009-07-17 2014-08-29 Japan Tobacco Inc. Triazolopiridinova spojina in njeno delovanje kot zaviralec prolil-hidroksilaze in induktor produkcije eritropoietina
EP3698794A1 (en) * 2009-11-06 2020-08-26 Aerpio Therapeutics, Inc. Compositions and methods for treating colitis
WO2014181813A1 (ja) * 2013-05-10 2014-11-13 武田薬品工業株式会社 複素環化合物
EP3414234B1 (en) 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112689637A (zh) * 2018-09-13 2021-04-20 橘生药品工业株式会社 咪唑并吡啶酮化合物

Also Published As

Publication number Publication date
US20230167108A1 (en) 2023-06-01
JPWO2021182490A1 (https=) 2021-09-16
AU2021233433A1 (en) 2022-10-06
KR20220152276A (ko) 2022-11-15
CN115279761A (zh) 2022-11-01
CA3169000A1 (en) 2021-09-16
EP4091670A1 (en) 2022-11-23
JP7566008B2 (ja) 2024-10-11
WO2021182490A1 (ja) 2021-09-16
EP4091670A4 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
JP6959663B2 (ja) Ｆｇｆｒ阻害剤としての複素環化合物
CN110088105B (zh) Jak家族激酶的小分子抑制剂
CN104797581B (zh) 杂芳基炔烃化合物及其应用
CN114057771B (zh) 大环化合物及其制备方法和应用
KR20240004634A (ko) 삼환식 유비퀴틴 특이적 프로테아제 1 억제제 및 이의 용도
CN111018846B (zh) 化合物晶型
JP2023504866A (ja) 大環構造を有するフッ素含有複素環誘導体およびその用途
WO2020228635A1 (zh) 一种egfr激酶抑制剂及其在制备抗癌药物方面的应用
IL298132A (en) Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1h-benzo[d]imidazol-2-yl)thieno[2,3-b]pyridin-6(7h)-one
CN106660970B (zh) 喹唑啉衍生物
CN102140093A (zh) 吡啶酮酰胺类衍生物、其制备方法及其在医药上的应用
CN112313233A (zh) Jak家族激酶的小分子抑制剂
CN112010839B (zh) 靶向丝/苏氨酸激酶抑制剂的晶型
CN115279761B (zh) 咪唑并吡啶酮化合物或其盐的晶体
WO2019189766A1 (ja) 新規ビアリールアミド誘導体
CN111718325A (zh) 一种2,4,5-取代嘧啶类化合物及其制备方法和应用
CN115244054B (zh) 次黄嘌呤化合物的晶体
HK40083277A (en) Crystal of imidazopyridinone compound or salt thereof
CN106146468B (zh) 吡啶酮类蛋白激酶抑制剂
KR20220143666A (ko) 다환 역형성 림프종 키나아제 억제제의 결정형
KR102959367B1 (ko) Ep4 길항제 화합물, 이의 염, 다형체 및 용도
US20260008776A1 (en) Crystal form and salt form of five-membered-fused six-membered compound, preparation method, pharmaceutical composition, and use
CN110483523B (zh) 一种吡唑并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
WO2025223470A1 (zh) 一种polq抑制剂在制备治疗或预防肿瘤药物中的应用
CN121108109A (zh) 一种靶向alk蛋白的protac化合物及其抗肿瘤应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40083277

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant